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Summary
The recent introduction of newborn screening for severe
primary T and B cell deficiencies in Switzerland allows
rapid identification of patients with severe combined im-
munodeficiency (SCID). Outcomes for SCID are greatly
improved by early diagnosis and treatment with allogeneic
haematopoietic stem cell transplantation or, in selected
cases, gene therapy. National centralised newborn
screening is performed in Switzerland since January 2019
using a combined T cell receptor excision circles (TREC)
/ κ-deleting recombination excision circles (KREC) assay,
also revealing infants with non-SCID severe T and B cell
disorders, who are often diagnosed with a substantial de-
lay. Here, we outline the screening procedure currently
performed in Switzerland and give recommendations for
diagnostic evaluations and precautionary measures
against infection in children with abnormal screening test
results.
Keywords: newborn screening, primary immunodeficien-
cy, inborn errors of immunity, T cells, B cells, TREC,
KREC, Severe combined immunodeficiency, agamma-
globulinaemia
Introduction
Severe combined immunodeficiency (SCID) is one of the
most severe forms of primary immunodeficiency (PID)
and is considered a paediatric emergency. SCID was first
described in Switzerland in the 1950s [1, 2] by the
founders of Swiss Paediatric Immunology as “Swiss-type
agammaglobulinaemia”. The treatment of choice for SCID
is allogeneic haematopoietic stem cell transplantation
(HSCT) or, in selected cases, gene therapy. Of note, one of
the most important factors for achieving high HSCT cure
rates is a good clinical condition of the child at time of
transplant, i.e., absence of active infection. With early di-
agnosis and treatment of SCID patients at an experienced
transplant centre prior to the onset of infection, high cure
rates of 80–95% can be achieved [3–6]. However, there is
a considerable number of undiagnosed patients, many of
whom die before treatment can be started. Therefore, new-
born screening for severe primary T and B cell deficiencies
was introduced in Switzerland on the 1 January 2019. Test-
ing is performed centrally in the Swiss Newborn Screening
(NBS) Laboratory at the University Children's Hospital in
Zurich.
SCID and other severe T cell diseases (here referred to as
combined immunodeficiency, CID) are disorders of T cell
development and can be associated with additional defects
such as B and natural killer (NK) cell deficiency. Affected
infants appear healthy at birth but typically develop life-
threatening bacterial, viral, fungal or opportunistic infec-
tions, persistent diarrhoea and failure to thrive within the
first weeks and months of life [7–9]. If left untreated, se-
vere T cell disorders are usually fatal in the first year of
life. Advances in cellular treatments, mainly HSCT, and





DBS dried blood spots
GA gestational age
HSCT haematopoietic stem cell transplantation
IgG immunoglobulin G
KREC kappa-deleting recombination excision circles
MHC major histocompatibility complex
MMR measles, mumps and rubella
NBS newborn screening
PID primary immunodeficiency
PNP purine nucleoside phosphorylase
SCID severe combined immunodeficiency
TREC T cell receptor excision circles
ZAP-70 zeta-chain-associated protein kinase 70
The recommendations in
this guideline were en-
dorsed by the Paediatric In-
fectious Disease Group of
Switzerland (PIGS), the
Swiss Society of Neonatol-
ogy (SSN) and the Swiss
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of novel therapeutics have considerably improved the sur-
vival and quality of life of these patients [10].
Severe isolated disorders of B cell development typically
result in absent B cells in the peripheral blood and low or
absent antibody levels (hypo- or agammaglobulinaemia).
Due to materno-fetal transfer of IgG antibodies, young in-
fants with isolated B cell deficiency are temporarily pro-
tected against infections despite a lack of endogenous an-
tibody production. This leads to a delay in the presentation
of clinical symptoms, most commonly due to infections af-
fecting the respiratory tract, until the age of 3–6 months af-
ter maternal antibodies have waned [11, 12].
The estimated incidence of severe forms of T and B cell
deficiencies requiring immediate attention is variable be-
tween different populations and settings, but is expected
to be around 1:50,000 live births for SCID and 1:10,000
live births for severe T cell lymphopenia of other origin
[13–16]. SCID and other T cell disorders may be associ-
ated with syndromal features or congenital heart defects,
such as cartilage-hair hypoplasia, ataxia telangiectasia or
DiGeorge syndrome (22q11.2 deletion syndrome), the lat-
ter representing a relatively common PID characterised by
thymus hypo- or aplasia, which is treated by thymus trans-
plantation rather than HSCT.
Screening
Switzerland’s newborn screening programme for severe
primary T and B cell deficiencies is based on a com-
mercially available assay (TREC-KREC-ACTB, “SPOT-
it” Kit, ImmunolVD, Stockholm, Sweden), which quan-
tifies T cell receptor excision circles (TRECs) and
kappa-deleting recombination excision circles (KRECs) by
means of a real-time polymerase chain reaction (PCR) test
from dried blood spots (DBS) collected as part of the na-
tional centralised newborn screening programme (Guthrie
cards) [17, 18].
TRECs are small ring-shaped DNA fragments that are pro-
duced as waste products during somatic recombination of
the T cell receptor gene locus upon T cell maturation in
the thymus [19]. The number of TRECs in the peripheral
blood correlates well with the number of freshly formed
naïve T cells, making the TREC test suitable for detecting
disorders in T cell development. In healthy infants, TRECs
are produced in large numbers, whereas in infants with
SCID or severe T cell lymphopenia TRECs are either not
or only barely detectable. Similarly, KRECs develop dur-
ing the maturation and somatic recombination of the B cell
receptor locus, and their copy number correlates with the
number of freshly formed naïve B cells [20].
The quality marker beta-actin is used as a positive test con-
trol to evaluate and ensure the methodological success of
the measurement of TREC/KREC copy numbers and is al-
ways run alongside the TREC/KREC test. The thresholds
for both TRECs and KRECs recommended by the manu-
facturer have been cautiously adapted by the Swiss NBS
centre for the first year of screening, to allow sufficient
sensitivity while keeping the false-positive rate as low as
possible:
– TRECs: abnormal if <10 copies/punch of DBS
– KRECs: abnormal if <6 copies/punch of DBS
– (beta-actin: normal if >1000 copies/punch of DBS)
The combined TREC/KREC screening is known to miss
certain potentially severe functional (as opposed to above
mentioned numerical) T cell deficiencies such as zeta-
chain-associated protein kinase 70 (ZAP-70) deficiency,
major histocompatibility complex (MHC) class II deficien-
cy, as well as milder forms of adenosine deaminase (ADA)
or purine nucleoside phosphorylase (PNP) deficiency that
clinically present with a late onset [21], and is also not sen-
sitive enough to detect milder forms of T and B cell de-
ficiency. In addition, the TREC/KREC assay is not an ap-
propriate method for detecting disorders that affect other
elements of the immune system, such as neutrophil or com-
plement diseases, or disorders of innate immunity.
Diagnostic procedure in the case of abnormal
screening results
TREC/KREC testing
As a screening test may only give an indication of potential
diseases, confirmatory testing is required after an abnormal
screening result. Testing is performed stepwise depending
on the findings and the severity of possible outcomes (fig.
1). Abnormal screening results are reported to the physi-
cians of the Department of Immunology at the University
Children’s Hospital Zurich during the operating hours of
the Newborn Screening Laboratory (Monday to Friday
8:00–17:00). Parents and local healthcare professionals are
then immediately informed and subsequent management
planned.
In the case of undetectable TRECs (0–1 TREC copy per
punch of DBS, i.e., a so-called “urgent-positive” result
with very high suspicion of SCID), families are preferably
seen within 24–48 hours in the immunology outpatient
clinic at the University Children’s Hospital Zurich or, ex-
ceptionally, in another immunology department highly ex-
perienced in the care of PID patients in the proximity of
the family. A longer delay is acceptable in situations with
low but detectable TRECs/KRECs, but patients with low
TRECs should still be seen within 72 hours of notification.
In patients with low or undetectable KRECs, a follow-up
NBS card measurement is performed 10–14 days later by
the midwife, the primary-care paediatrician or a hospital
nearby, after the family and involved healthcare profes-
sionals have been informed. In the event of continuing
abnormal NBS results, families are invited for a consul-
tation in the Immunology outpatient clinic at the Univer-
sity Children’s Hospital Zurich. If the risk of primary B
cell deficiency is low, such as in the case of low but de-
tectable KRECs and maternal immunosuppression during
pregnancy, there is the possibility to discuss with the par-
ents whether to measure another NBS card before further
investigations (fig. 1).
Low KRECs in particular can be due to secondary causes
such as maternal immunosuppression during pregnancy
(e.g., azathioprine, rituximab) and therefore careful his-
tory-taking is required [11]. Information on maternal im-
munosuppression is requested on the new Guthrie cards,
which have been available in Switzerland since the start of
2019.
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Abnormal TREC results may sometimes be associated
with other (not primarily immunological) diseases such as
prematurity, hydrops fetalis, congenital heart disease, tri-
somy 21, sepsis, malformations, chylothorax or congeni-
tal syndromes, although an associated immunodeficiency
must still be ruled out [22, 23].
Preterm infants with abnormal TREC/KREC testing
Preterm infants may have low TREC and/or KREC levels
due to the immaturity of their immune system. Since
preterm infants may nonetheless suffer from SCID,
neonates with undetectable TRECs should still be urgently
evaluated by a paediatric immunologist experienced in the
management of PID and SCID, and relevant investigations
must be performed. Preterm infants with low but de-
tectable TRECs may be followed clinically and the TREC/
KREC screening repeated every 2 weeks until results nor-
malised or they reach 37 weeks adjusted gestational age, at
which time lymphocyte enumeration via flow cytometry is
performed [24].
Breastfeeding
In the case of abnormal TREC results, it is important to
rapidly assess whether the infant’s mother has already ac-
quired cytomegalovirus (CMV) infection, because only
those mothers who are CMV seronegative should be al-
lowed to breastfeed (table 1). As preterm infants particular-
ly benefit from human milk [25–27] and may remain in the
evaluation phase longer while repeated TREC/KREC test-
ing is performed, infants with low (but measurable) TREC
levels may be given pasteurised human milk (Holder pas-
teurisation: 62.5°C for 30 min), even when the infant’s
mother is CMV seropositive.
Diagnostic follow-up investigations
Whenever possible, the initial clinical assessment is per-
formed by a SCID-experienced paediatric immunologist at
the Swiss national HSM (highly specialised medicine) ref-
erence centre for Paediatric Immunology at the Universi-
ty Children's Hospital Zurich. If this is not possible (e.g.,
for premature or non-transportable infants), an on-call im-
munologist / HSCT specialist is available round the clock
to discuss the necessary measures (via the hospital switch-
board +41 44 266 7111).
The evaluation of an infant with an abnormal TREC result
includes a thorough medical history to determine if there
were any prenatal exposures or perinatal illnesses impact-
ing the screening. For well-appearing full-term infants, the
family history is reviewed specifically for deaths in ear-
ly childhood or fetal loss during pregnancy, significant in-
fectious history in siblings and close family members, as
well as consanguinity. A thorough physical examination is
performed, whenever possible together with a clinical ge-
neticist, including evaluation for dysmorphic features, skin
rashes, absence of lymphoid tissue, and somatic growth.
In addition to the clinical evaluation, a fresh blood sample
for lymphocyte immunophenotyping including naïve
CD4+CD31+ T cells (representing recent thymic emi-
grants) is taken at the initial consultation (table 2 top pan-
el). Whenever possible, this is performed in the Immunol-
ogy Diagnostics Laboratory of the HSM centre for
Figure 1: Screening algorithm –TREC/KREC screening and initial diagnostic evaluation.
Review article: Biomedical intelligence Swiss Med Wkly. 2020;150:w20254
Swiss Medical Weekly · PDF of the online version · www.smw.ch
Published under the copyright license “Attribution – Non-Commercial – No Derivatives 4.0”.
No commercial reuse without permission. See http://emh.ch/en/services/permissions.html.
Page 3 of 6
Paediatric Immunology at the University Children's Hospi-
tal Zurich to ensure comparability of the results. In addi-
tion to lymphocyte immunophenotyping, further work-up
is required to narrow down the differential diagnosis and
determine the severity of the disease (table 2 second pan-
el).
Genetic testing
In the case of suspected SCID, genetic testing is performed
through whole-exome sequencing and additional Sanger
sequencing of the two RNA genes RMRP and RNU4ATAC
at an accredited laboratory of medical genetics with expe-
rience in the analysis of variants in PID genes to identify
the underlying mutation [12]. Results are usually available
within 2–3 weeks. Generally, blood samples are also taken
from both parents in addition to the blood sample from the
infant in order to carry out family segregation analysis. If
microdeletion syndromes (such as microdeletion 22q11.2
/ DiGeorge syndrome) are suspected, a targeted multiplex
ligation-dependent probe amplification (MLPA) assay or a
genome-wide microarray analysis is also performed.
In the case of isolated abnormal KREC levels suggesting
a B cell disorder, genetic investigations through whole-
exome sequencing may be used to identify mutations in
immune genes that are known to cause agammaglobuli-
naemia or severe hypogammaglobulinaemia [12].
Management of infants with severe T cell lymphopenia
(suspected SCID)
Infants with severe T cell lymphopenia should be placed in
protective isolation while in hospital and blood products,
if required, should be leucocyte-depleted and irradiated [8,
9]. If at home, families of affected patients should be ap-
propriately instructed on how they can reduce the risk of
infection, including good hand hygiene and the avoidance
of public places and day-care, limiting contact with young
children and unvaccinated persons, and boiling drinking
water [24]. To further reduce the risk of infection, infants
are given antimicrobial prophylaxis, intravenous or sub-
cutaneous immunoglobulin replacement, and prophylax-
is with palivizumab during the respiratory syncytial virus
season (table 2 third panel).
Live vaccines are contraindicated for infants with severe
T cell lymphopenia, and inactivated vaccines are unlikely
to be effective and are therefore not recommended. Family
members, however, should be actively assessed for in-
complete vaccine histories, and catch-up or booster vac-
cines administered if needed (table 2 bottom panel). This
includes the annual influenza, pertussis, live attenuated
measles, mumps and rubella (MMR) and varicella zoster
vaccines. A recent extensive analysis has found no ev-
idence of human-to-human transmission of the measles
vaccine virus, so this vaccine can be given safely to people
who are in contact with immunocompromised patients
[28]. The transmission risk for varicella vaccine strain is
extremely low and published evidence shows that trans-
mission is only possible when skin lesions occur [29].
Hence, varicella vaccination is recommended for all non-
immune contact persons of severely immunocompromised
patients. If a vaccinated person develops a rash (local or
systemic), contact with immunocompromised patients
should be avoided until the rash has resolved to further de-
crease the chance of vaccine strain transmission. If close
contacts (such as siblings) receive the live rotavirus vac-
cine, contact with their diapers should be avoided for 2–4
weeks after vaccination [30, 31].
Conclusions
Inclusion of the screening test for severe primary T and B
cell disorders in the Swiss routine newborn screening pan-
el represents a major step forward in improving the clin-
ical management of these rare conditions, which are oth-
erwise associated with significant morbidity and mortality.
Early detection of SCID patients allows rapid implementa-
tion of precautions to reduce acquisition of infectious or-
ganisms by avoidance of viral vaccines and initiation of
antimicrobial prophylaxis as well as IgG replacement ther-
apy. In addition, pathogen transmission by maternal milk,
family members and close contacts to immunodeficient pa-
tients can be reduced through pre-emptive vaccination and
other relevant measures.
Table 1: Breastfeeding in infants with abnormal screening for severe primary immunodeficiencies.
Investigations (as soon as possible)
Mother: CMV serology from peripheral blood (or from serum collected during pregnancy)
Infant: CMV-PCR from urine (or peripheral blood), not Guthrie card
KREC low/undetectable and TREC normal and ADA/PNP normal
Breast milk can be given (irrespective of the mother’s CMV status and the infant’s gestational age)
TREC low / undetectable
1. Evaluation phase
Gestational age Mother CMV seropositive* Mother CMV seronegative
TREC low
but measurable
<37 weeks No breastfeeding, pasteurised breast milk
possible
Breast milk possible‡
≥37 weeks No breast milk†
TREC not measurable Any gestational age No breast milk† Breast milk possible‡
2. Suspected SCID
Child CMV+ Child CMV−
Mother CMV+ No breast milk No breast milk
Mother CMV− Breast milk possible Breast milk possible‡
ADA = adenosine deaminase; CMV = cytomegalovirus; KREC = kappa-deleting recombination excision circles; PCR = polymerase chain-reaction; PNP = purine nucleoside
phosphorylase; SCID = severe combined immunodeficiency; TREC = T cell receptor excision circles; * Parents should be informed about all routes of CMV transmission (e.g.,
saliva) and clinical signs of CMV infection. † During the evaluation phase, breast milk can be discarded or frozen. ‡ Parents should be informed about possible CMV transmission
routes and precautions to avoid CMV infection; regular testing for CMV through CMV-PCR in urine is recommended for these children (e.g. weekly in the first 4 weeks of life and
2-weekly thereafter). The mother should also be regularly tested for CMV if initially seronegative.
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Early diagnosis of SCID results not only in a better clinical
outcome since uninfected SCID patients exhibit superior
cure rates after HSCT [4, 32], but also increases our under-
standing of the epidemiology of these rare disorders. The
Table 2: Follow-up investigations for infants with suspected severe primary T and B cell deficiencies.
1. Initial diagnostic work-up
History, clinical examination
Full blood count, lymphocyte immunophenotyping, ADA/PNP, repeat DBS (Guthrie card), collect DNA (from blood)
Always or at least in case of known syndromal aspects: aim to perform first consultation together with a clinical geneticist
Definitions used for categorisation of T-cell disorders:
Total CD3+ T cells Naïve CD4+ T cells Disorder Action
>1500/µl and >200/µl Healthy No further testing
≤1500/µl >200/µl Suspected CID Partial workup according to findings (see ticks below in column far
right)
≤1500/µl* ≤200/µl Suspected SCID Full workup (see below)
* In some cases, total T cell numbers can be higher (even normal) due to maternal engraftment or incomplete SCID with peripheral expansion of autologous T cells
2. Diagnostic workup of patients with suspected SCID
Investigation Details Sample Comments CID
Step 1
Haematology Full blood count with differential 0.5 ml EDTA Eosinophilia in (some) SCID; lymphopenia x
Chemistry Electrolytes incl. ionised Ca2+, total bilirubin,
ASAT, ALAT, albumin
0.5 ml Li-Hep Hypocalcaemia in (some) DiGeorge patients x
Lymphocyte immunophenotyping B, T, NK cells, T-cell subpopulations 1–2 ml EDTA T cells ± B/NK cells low in classical SCID; suspect mater-
nal engraftment if T cells higher than expected and/or ex-
panded memory T-cell pool and low/absent naive T cells
x
Antibody concentrations Total IgA, IgG, IgM (and IgE) concentrations 0.5–1 ml serum IgG can be normal (maternal transfer to the fetus) x
Step 2
ADA, PNP Enzyme activity 0.5 ml EDTA Low in ADA/PNP deficiency x
T-cell function In vitro T-cell proliferation (mitogen) assay 1–2 ml Li-Hep Can be normal in incomplete SCID x
Gamma-H2AX test Radiosensitivity assay 2 ml Abnormal in ataxia telangiectasia
TCRvβ repertoire CDR3 spectratyping (or flow cytometry) DNA Especially in incomplete SCID and Omenn syndrome
Blood group AB0 blood group testing 0.5 ml EDTA In preparation for HSCT
HLA typing Prefer on sorted myeloid cells if maternal en-
graftment suspected
4.5 ml ACD On patient and siblings/parents; in preparation for HCST
Maternal engraftment When suspected (e.g., discrepancy between
low TREC and higher-than-expected T-cell
counts or low/absent naive CD4 T cells com-
bined with an expanded memory T-cell pool)
2 ml EDTA
5 ml EDTA (moth-
er)
HLA phenotyping by flow cytometry on infant/mother pair
VNTR (girls) or XY-FISH (boys) on sorted infant cells and
DNA/cells of the mother
Genetics Whole exome sequencing ± DNA microarray
± other targeted tests
0.5 ml EDTA In consultation with the clinical geneticist; blood/DNA also
from parents (and siblings if indicated)
(x)
Microbiological investigations
Serology (maternal blood) HIV combo-screen, HBV (HbS, anti-HbS, anti-
HbC)
HCV Screen (anti-HCV IgG/M), CMV IgG
Can be requested from stored serum collected during
pregnancy
x
CMV status of child CMV PCR Urine (from bag) x
Additional testing if clinically indicated x
3. Recommended antimicrobial prophylaxis for patients with SCID
Aim Medication Comments
PJP prophylaxis Cotrimoxazole 18 mg/kg q 12 h (on 3 days per
week)
Leucovorin 15 mg/m2 q 1 week
Start when total bilirubin below 2× the upper limit of the reference range
Regularly check CBC and liver function tests incl. total bilirubin
(x)
Fungal prophylaxis Amphotericin B p.o. 100 mg q 8 h OR
Fluconazole p.o. 6 mg/kg (q 48 h <1 mo old, q
24 h ≥1 mo)
Amphotericin B p.o.: little or no absorption from the gastrointestinal tract (x)
RSV prophylaxis Palivizumab 15 mg/kg i.m. q 4 weeks Prophylaxis during RSV season
IgG replacement i.v. Ig q 3-4 weeks or s.c. Ig q 1 week Adapted to IgG serum concentration (x)
4. Vaccinations
Live vaccines (MMR, VZV, rotavirus, yellow fever, BCG, oral typhoid, nasal influenza)
SCID patient Contraindicated (x)
Family members / close contacts Check vaccination status and test serology if unclear; a complete course of MMR and VZV vaccination recommended;
MMR vaccine can be given any time; there should be no contact to a SCID patient if a VZV immunised person develops a
rash as long as the rash persists
x
Inactivated vaccines
SCID patient Unlikely of benefit – not recommended
Family members / close contacts Annual influenza vaccine and other routine vaccines as per national immunisation schedule x
ACD = acid citrate dextrose; ADA = adenosine deaminase; ALAT = alanine aminotransferase; ASAT = aspartate aminotransferase; BCG = bacillus Calmette-Guérin; SBS =
complete blood count; CID = combined immunodeficiency; CMV = cytomegalovirus; DBS = dried blood spots; EDTA = ethylenediamine tetraacetic acid; FISH = fluorescence in
situ hybridisation; HIV = human immunodeficiency virus; HbC = HBV core antigen; HbS = HBV surface antigen; HBV = hepatitis B virus; HCV = hepatitis C virus; HLA = human
leucocyte antigen; HSCT = haematopoietic stem cell transplantation; Ig = immunoglobulin; Li-Hep = lithium heparin; MMR = measles, mumps, rubella; NK = natural killer; PCR
= polymerase chain-reaction; PJP = Pneumocystis jirovecii pneumonia; PNP = purine nucleoside phosphorylase; RSV = respiratory syncytial virus; SCID = severe combined
immunodeficiency; TREC = T cell receptor excision circles; VNTR = variable number tandem repeat; VZV = varicella-zoster virus
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establishment of the Swiss SCID newborn screening pro-
gramme has also helped in the refinement of better and
more efficient management and follow-up guidelines of af-
fected patients and their families by a dedicated team of
healthcare professionals including midwives, social work-
ers, psychologists, specialised nurse-practitioners, HSCT
specialists, neonatologists, paediatric intensivists, general
paediatricians, medical geneticists, and infectious disease
and immunology specialists.
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